Palvella Therapeutics (PVLA) EBIT (2013 - 2026)
Palvella Therapeutics (PVLA) posted quarterly EBIT of -$14.9 million for Q1 2026, down 88.73% year-over-year from -$131.8 million in Q1 2025, and down 31.41% quarter-over-quarter from -$11.3 million in Q4 2025.
Palvella Therapeutics (PVLA) EBIT (2013 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported EBIT for 14 consecutive years, with -$14.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, EBIT fell 88.73% year-over-year to -$14.9 million; the TTM figure through Mar 2026 stood at -$45.6 million (down 125.6% YoY), while the FY2025 annual figure was -$38.6 million, down 173.87% from the prior year.
- EBIT slipped to -$14.9 million in Q1 2026 per PVLA's latest filing, from -$11.3 million in the prior quarter.
- Across five years, EBIT topped out at $13.4 million in Q4 2023 and bottomed at -$15.5 million in Q1 2023.
- Historically, EBIT has averaged -$7.2 million across 5 years, with a median of -$9.2 million in 2025.
- Annual changes were most pronounced in 2023 — EBIT soared 216.21% — and 2025, when it plunged 347.47%.
- Palvella Therapeutics' EBIT stood at -$11.5 million in 2022, then jumped by 216.21% to $13.4 million in 2023, then tumbled by 132.62% to -$4.4 million in 2024, then sank by 158.91% to -$11.3 million in 2025, then sank by 31.41% to -$14.9 million in 2026.
- Business Quant data shows PVLA's EBIT at -$14.9 million in Q1 2026, -$11.3 million in Q4 2025, and -$10.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | -21.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.41 Mn |
| Mar 31, 2026 | -14.86 Mn |
| Dec 31, 2025 | -11.30 Mn |
| Sep 30, 2025 | -10.18 Mn |
| Jun 30, 2025 | -9.25 Mn |
| Mar 31, 2025 | -7.87 Mn |
| Dec 31, 2024 | -4.37 Mn |
| Sep 30, 2024 | -5.06 Mn |
| Jun 30, 2024 | -2.91 Mn |
| Mar 31, 2024 | -1.76 Mn |
| Dec 31, 2023 | 13.39 Mn |
| Sep 30, 2023 | -11.81 Mn |
| Jun 30, 2023 | 2.06 Mn |
| Mar 31, 2023 | -15.51 Mn |
| Dec 31, 2022 | -11.52 Mn |
| Sep 30, 2022 | -12.17 Mn |
| Jun 30, 2022 | -12.33 Mn |
| Mar 31, 2022 | -7.46 Mn |
| Dec 31, 2021 | -11.00 Mn |
| Sep 30, 2021 | -19.01 Mn |